SCHEMBL816

SCHEMBL816

Cc1ccc(-c2ccccc2C=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XDH P47989 1/20 0.51
ALDH1A1 P00352 2/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 1/20 0.48
THRB P10828 1/20 0.48
BLM P54132 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
CYP2A6 P11509 1/20 0.43
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TRIM24 O15164 1/20 0.40
TRIM33 Q9UPN9 1/20 0.40
HPRT1 P00492 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Toluene SCHEMBL27617474 0.90 TSHR (0.48) XDHALDH1A1TSHRMEN1KMT2A
SCHEMBL305369 0.89 MEN1 (0.49) XDHALDH1A1TSHRMEN1KMT2A
SCHEMBL30497064 0.89 LMNA (0.60) XDHALDH1A1TSHRMEN1KMT2A
SCHEMBL11768743 0.89 LMNA (0.60) XDHALDH1A1TSHRMEN1KMT2A
Toluene SCHEMBL27700958 0.88 TSHR (0.47) XDHALDH1A1TSHRMEN1KMT2A
Toluene SCHEMBL27652430 0.86 TSHR (0.45) XDHALDH1A1TSHRMEN1KMT2A
Toluene SCHEMBL27481880 0.86 TSHR (0.45) XDHALDH1A1TSHRMEN1KMT2A
Toluene SCHEMBL27835105 0.86 TSHR (0.45) XDHALDH1A1TSHRMEN1KMT2A
SCHEMBL30924956 0.83 XDH (0.54) XDHALDH1A1TSHRMEN1KMT2A
SCHEMBL977958 0.83 XDH (0.54) XDHALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250187036-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2025-06-12 US claimed
EP-4486515-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA Sicpa Holding SA (CH) 2025-01-08 EP claimed
WO-2023161464-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2023-08-31 WO claimed
EP-1066248-B1 METHYL-BIPHENYL DERIVATIVES, PREPARATION METHOD AND USE SANOFI SYNTHELABO (FR) 2003-06-18 EP claimed
US-6417400-B1 O-(P-TOLYL)-BENZALDIMINE IS REACTED WITH HYDROXYLAMINE SALT TO FORM O-(P-TOLYL)-BENZALDOXIME; O-(P-TOLYL)-BENZONITRILE CHEMICAL INTERMEDIATES FOR DRUGS; OXIMINATION, IMINATION SANOFI-SYNTHELABO (FR) 2002-07-09 US claimed
US-20250187036-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2025-06-12 US disclosed
CN-119462519-A Dihydropyrimidine thioketone compound and application thereof in resisting porcine epidemic diarrhea virus 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 2025-02-18 CN disclosed
EP-4486515-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA Sicpa Holding SA (CH) 2025-01-08 EP disclosed
WO-2023161464-A1 METHODS FOR PRODUCING OPTICAL EFFECT LAYERS COMPRISING MAGNETIC OR MAGNETIZABLE PIGMENT PARTICLES AND EXHIBITING ONE OR MORE INDICIA SICPA HOLDING SA (CH) 2023-08-31 WO disclosed
EP-3822268-A1 SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS Bayer Aktiengesellschaft (DE) 2021-05-19 EP disclosed
US-10654878-B2 Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2020-05-19 US disclosed
US-20190031693-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LES LABORATOIRES SERVIER (FR) 2019-01-31 US disclosed
EP-0459136-A1 Benzimidazole derivatives, their production and use Takeda Chemical Industries, Ltd. (JP) 1991-12-04 EP disclosed
US-5019479-A Photoresists for integrated circuits JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1991-05-28 US disclosed
EP-0324377-A2 Angiotensin II receptor blocking imidazoles and combinations thereof with diuretics and NSaids E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-19 EP disclosed
WO-1989006233-A1 ANGIOTENSIN II RECEPTOR BLOCKING IMIDAZOLES AND COMBINATIONS THEREOF WITH DIURETICS AND NSAIDS E.I. DU PONT DE NEMOURS AND COMPANY (US) 1989-07-13 WO disclosed
EP-0253310-A2 Angiotensin II receptor blocking imidazoles E.I. DU PONT DE NEMOURS AND COMPANY (US) 1988-01-20 EP disclosed
EP-0239423-A2 Positive type radiation-sensitive resin composition JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1987-09-30 EP disclosed
EP-0227487-A2 Positive type radiation-sensitive resin composition JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1987-07-01 EP disclosed
US-4137259-A SILVER VANADATE, IRON VANADATE STAMICARBON, B.V. (NL) 1979-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654878-B2 Compounds of phosphinanes and azaphosphinanes, a process for their preparation and pharmaceutical compositions containing them TK1, AK1, PHKA1 XDH 1074/4885ALDH1A1 1469/4885TSHR 573/4885
US-20190031693-A1 COMPOUNDS OF PHOSPHINANES AND AZAPHOSPHINANES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AK1, TK1, PHKA1 XDH 949/4885ALDH1A1 1477/4885TSHR 542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.